KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Purchases 73,649 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par acquired 73,649 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was purchased at an average price of $9.29 per share, with a total value of $684,199.21. Following the transaction, the insider now owns 5,086,445 shares in the company, valued at $47,253,074.05. This represents a 1.47 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 10th, Venrock Healthcare Capital Par bought 4,137 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average cost of $9.14 per share, with a total value of $37,812.18.
• On Monday, February 3rd, Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock. The shares were acquired at an average price of $9.22 per share, for a total transaction of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock. The shares were bought at an average price of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV opened at $9.53 on Friday. The business has a 50-day moving average of $8.75 and a 200-day moving average of $10.57. The stock has a market capitalization of $470.97 million, a price-to-earnings ratio of -2.62 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. On average, sell-side analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on KALV. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price objective for the company. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. Bank of America began coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target on the stock. JMP Securities started coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $23.80.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. State Street Corp lifted its stake in KalVista Pharmaceuticals by 68.1% in the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after acquiring an additional 515,179 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in KalVista Pharmaceuticals during the fourth quarter worth about $634,000. Vestal Point Capital LP increased its position in KalVista Pharmaceuticals by 73.9% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after buying an additional 1,700,000 shares during the last quarter. Barclays PLC raised its stake in KalVista Pharmaceuticals by 418.5% in the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after buying an additional 54,257 shares during the period. Finally, Readystate Asset Management LP acquired a new stake in shares of KalVista Pharmaceuticals in the third quarter valued at approximately $2,084,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).